Diabetes drugs compared — where they act, hypoglycemia, weight and outcomes
Verified · Oct 2026Each drug pulls a different lever: the pancreas (insulin release), the liver, muscle and fat, the gut, or the kidney. Whether a drug forces insulin out regardless of glucose decides its hypoglycemia risk, and its site of action largely predicts its harms.
Where each drug acts
Pancreas: sulfonylureas and the meglitinides close the β-cell ATP-sensitive K⁺ channel, so insulin is released; DPP-4 inhibitors and the GLP-1 agonists raise insulin release only when glucose is high and lower glucagon. Liver: metformin decreases hepatic glucose production and improves insulin sensitivity, leaving insulin secretion unchanged. Muscle and fat: pioglitazone activates PPAR-γ and reduces insulin resistance; insulin itself drives glucose uptake through GLUT4.
Gut: the α-glucosidase inhibitors block brush-border enzymes so carbohydrate is absorbed later; pramlintide (an amylin analog) and the GLP-1 agonists slow gastric emptying and increase satiety. Kidney: SGLT2 inhibitors block glucose reabsorption in the proximal tubule, so glucose leaves in the urine.
Why some cause hypoglycemia and others do not
Hypoglycemia is the most common adverse reaction of all insulins. Sulfonylureas cause it because they release insulin regardless of glucose; it can be severe after a missed meal or exercise. Meglitinides close the same channel, but their release is glucose-dependent and short, so a dose is skipped with a skipped meal.
The incretin drugs raise insulin only when glucose is high, so on their own they rarely cause hypoglycemia. Metformin, pioglitazone, the α-glucosidase inhibitors and the SGLT2 inhibitors do not force insulin out, so hypoglycemia is unlikely alone and mainly appears when they are added to insulin or a secretagogue, whose dose may need lowering. Pramlintide causes no hypoglycemia alone, but with mealtime insulin it carries a boxed warning for severe hypoglycemia.
On weight, the insulin-raising drugs (insulin, sulfonylureas, meglitinides) and pioglitazone add weight; metformin and the DPP-4 inhibitors are weight-neutral; the GLP-1 agonists, SGLT2 inhibitors and pramlintide lower it. The GLP-1 agonists and the SGLT2 inhibitors carry labeled cardiovascular or kidney outcome indications.
Comparison
Glucose-lowering drugs at a glance
| Class | Site and mechanism | Hypoglycemia on its own | Weight | Labeled CV or kidney outcome | Signature harm |
|---|---|---|---|---|---|
| Insulins | Insulin receptor (tyrosine kinase); GLUT4 uptake in muscle and fat; hepatic output ↓ | Yes — the most common adverse reaction | Gain | — | Hypoglycemia; hypokalemia (K⁺ shift into cells); lipodystrophy |
| Metformin | Liver: ↓ glucose production; ↑ insulin sensitivity; insulin secretion unchanged | Unlikely | Neutral (possibly modest loss) | — | GI upset; vitamin B12 deficiency; lactic acidosis (boxed) |
| Sulfonylureas | β-cell K-ATP closure → insulin regardless of glucose | Yes — most common; can be severe | Gain | — | Hypoglycemia (long-acting glyburide in older adults); UGDP cardiovascular-mortality warning |
| DPP-4 inhibitors | Block DPP-4 → own incretins last longer; glucose-dependent insulin, ↓ glucagon | Low | Neutral | — | Pancreatitis, arthralgia, bullous pemphigoid; heart-failure signal (saxagliptin, alogliptin) |
| GLP-1 and GIP/GLP-1 agonists | Incretin receptor agonists: glucose-dependent insulin, ↓ glucagon, slower gastric emptying, satiety | Low (counter-regulation preserved) | Loss | MACE reduction (semaglutide, liraglutide, dulaglutide, tirzepatide); kidney outcomes (semaglutide) | GI effects → kidney injury, aspiration; pancreatitis; thyroid C-cell tumors (boxed) |
| SGLT2 inhibitors | Proximal tubule: block glucose reabsorption → glucosuria | Mainly with insulin or secretagogues | Loss | Heart failure, chronic kidney disease, cardiovascular death (empagliflozin, dapagliflozin) | Euglycemic DKA; genital and urinary infections, Fournier gangrene; volume depletion |
| Pioglitazone | PPAR-γ agonist: ↓ insulin resistance in muscle, fat and liver | No | Gain (fat and fluid) | — | Fluid retention and heart failure (boxed); fractures; bladder cancer |
| α-Glucosidase inhibitors | Gut: brush-border α-glucosidase (and α-amylase) inhibition → slower carbohydrate absorption | No | May decrease (acarbose) | — | Flatulence, diarrhea; treat lows with glucose, not sucrose |
| Meglitinides | β-cell K-ATP closure — short, meal-timed insulin release | Yes | Gain | — | Hypoglycemia; repaglinide contraindicated with gemfibrozil |
| Pramlintide | Amylin analog: slower gastric emptying, ↓ postprandial glucagon, satiety | No (alone) | Loss in trials | — | Severe hypoglycemia with insulin (boxed); nausea |
— = no labeled outcome indication stated on the source pages.
Boxed warnings
| Class | Boxed warning | The reasoning |
|---|---|---|
| Metformin | Lactic acidosis | Risk climbs when metformin or lactate accumulates — renal impairment, hypoxic states, contrast, excess alcohol, hepatic impairment |
| GLP-1 and GIP/GLP-1 agonists | Thyroid C-cell tumors (in rodents) | Contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2 |
| Pioglitazone | Can cause or worsen congestive heart failure | Dose-related fluid retention; not recommended in symptomatic heart failure |
| Pramlintide | Severe hypoglycemia with insulin | Occurs within hours of a dose, especially in type 1 diabetes; the mealtime insulin dose is reduced |
High-yield
Practice questions
Q1A 64-year-old man with type 2 diabetes, heart failure with reduced ejection fraction and chronic kidney disease needs a second glucose-lowering drug with metformin.
Which choice is best supported?
- A.An SGLT2 inhibitor such as empagliflozin or dapagliflozin
- B.Pioglitazone, which improves heart failure
- C.Saxagliptin, which lowers heart-failure hospitalization
- D.Glipizide, because sulfonylureas carry a cardiovascular-mortality benefit
Show answer
A. An SGLT2 inhibitor such as empagliflozin or dapagliflozin — Empagliflozin and dapagliflozin are labeled to reduce cardiovascular death and heart-failure hospitalization in heart failure and to slow chronic kidney disease. Pioglitazone carries a boxed warning that it can cause or worsen congestive heart failure, and saxagliptin increased heart-failure hospitalization in its outcome trial. Sulfonylureas carry the UGDP special warning on increased cardiovascular mortality, not a benefit.
Q2A 76-year-old man with type 2 diabetes takes metformin, sitagliptin and glyburide. After a day of eating little because of a cold, he is found confused with a glucose of 42 mg/dL.
Which drug most likely caused the hypoglycemia, and why?
- A.Metformin, because it stimulates insulin secretion
- B.Sitagliptin, because it raises insulin regardless of glucose
- C.Sitagliptin, because it causes glucosuria
- D.Glyburide, because it releases insulin regardless of glucose and is long-acting
Show answer
D. Glyburide, because it releases insulin regardless of glucose and is long-acting — Sulfonylureas close the β-cell K-ATP channel and release insulin regardless of glucose, so a missed meal can cause severe hypoglycemia; glyburide, a long-acting agent, is on the Beers list for severe prolonged hypoglycemia in older adults. Metformin leaves insulin secretion unchanged and is unlikely to cause hypoglycemia alone, sitagliptin preserves incretins whose action is glucose-dependent, and glucosuria is the SGLT2 inhibitors’ mechanism, not sitagliptin’s.
Q3A 52-year-old woman with type 2 diabetes and obesity takes metformin. Her HbA1c is above target, and she asks for a second drug that will also help her lose weight.
Which add-on best fits her goal?
- A.Glipizide
- B.Pioglitazone
- C.Insulin glargine
- D.Semaglutide
Show answer
D. Semaglutide — GLP-1 receptor agonists such as semaglutide delay gastric emptying and increase satiety through the hypothalamus, and the class promotes weight loss compared with placebo; semaglutide reduces body weight. Weight gain is common with sulfonylureas such as glipizide, pioglitazone adds weight by expanding subcutaneous fat and retaining fluid, and weight gain is an adverse effect of insulin therapy.
Q4A student reviewing glucose-lowering drugs writes one boxed warning next to each of four drugs.
Which drug is matched with its boxed warning correctly?
- A.Pramlintide — severe hypoglycemia when used with insulin
- B.Metformin — thyroid C-cell tumors
- C.Liraglutide — lactic acidosis
- D.Pioglitazone — lactic acidosis
Show answer
A. Pramlintide — severe hypoglycemia when used with insulin — Pramlintide used with insulin increases the risk of severe hypoglycemia, particularly in type 1 diabetes, so the mealtime insulin dose is reduced when it is started. Metformin’s boxed warning is lactic acidosis, not thyroid tumors; liraglutide and the other GLP-1 agonists carry the thyroid C-cell tumor warning; and pioglitazone’s boxed warning is that thiazolidinediones cause or worsen congestive heart failure.
Sources
- Repaglinide tablets — FDA label — FDA / DailyMed
- Nateglinide tablets — FDA label — FDA / DailyMed
- Alpha-Glucosidase Inhibitors — StatPearls (NCBI)
- Symlin (pramlintide) — FDA label — FDA / DailyMed
- Insulin — StatPearls (NCBI)
- Biochemistry, Insulin Metabolic Effects — StatPearls (NCBI)
- Insulin Lispro — StatPearls (NCBI)
- Regular Insulin — StatPearls (NCBI)
- Humalog (insulin lispro) — FDA label — FDA / DailyMed
- Humulin R U-100 (insulin human) — FDA label — FDA / DailyMed
- Metformin hydrochloride tablets — FDA label — FDA / DailyMed
- Metformin — StatPearls (NCBI)
- Insulin, Medicines, & Other Diabetes Treatments — NIDDK (National Institutes of Health)
- Sulfonylureas — StatPearls (NCBI)
- Glipizide — StatPearls (NCBI)
- Glimepiride — StatPearls (NCBI)
- Glyburide — StatPearls (NCBI)
- Glipizide tablets — FDA label — FDA / DailyMed
- Glimepiride tablets — FDA label — FDA / DailyMed
- Glyburide tablets — FDA label — FDA / DailyMed
- Polypharmacy, drug–drug interactions and potentially inappropriate medications among older adults — Frontiers in Public Health via PMC
- Januvia (sitagliptin) — FDA label — FDA / DailyMed
- Tradjenta (linagliptin) — FDA label — FDA / DailyMed
- Saxagliptin tablets — FDA label — FDA / DailyMed
- Nesina (alogliptin) — FDA label — FDA / DailyMed
- Dipeptidyl Peptidase IV (DPP IV) Inhibitors — StatPearls (NCBI)
- Ozempic (semaglutide) injection — FDA label — FDA / DailyMed
- Rybelsus and Ozempic (semaglutide) tablets — FDA label — FDA / DailyMed
- Victoza (liraglutide) — FDA label — FDA / DailyMed
- Trulicity (dulaglutide) — FDA label — FDA / DailyMed
- Mounjaro (tirzepatide) — FDA label — FDA / DailyMed
- Glucagon-Like Peptide-1 Receptor Agonists — StatPearls (NCBI)
- Medullary Thyroid Cancer — StatPearls (NCBI)
- Jardiance (empagliflozin) — FDA label — FDA / DailyMed
- Farxiga (dapagliflozin) — FDA label — FDA / DailyMed
- Physiology, Glycosuria — StatPearls (NCBI)
- Actos (pioglitazone) — FDA label — FDA / DailyMed
- Acarbose tablets — FDA label — FDA / DailyMed
- Miglitol tablets — FDA label — FDA / DailyMed
- Thiazolidinediones — StatPearls (NCBI)
- Pioglitazone — StatPearls (NCBI)
- Rosiglitazone — StatPearls (NCBI)
- Repaglinide — StatPearls (NCBI)
Each class page compared lists its full sources; this page reuses facts verified there.
By LearnDrugs
Educational summary for medical students. Always verify against current prescribing information and guidelines. Not medical advice.